Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TITAN PHARMACEUTICAL (TTP) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (123)	3/23/2000 9:40:00 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 362

I know that Rick will laugh on my back, but I can?t pass without comment. biz.yahoo.com <<The increase in research and development expenditures for full-year 1999 versus full-year 1998 was a result of the excellent patient accrual and expansion of the clinical trial with CeaVac(TM) in Dukes D colorectal cancer to a Phase III study. Additionally, the pre-clinical evaluation of Spheramine(TM) was essentially completed in 1999, resulting in the initiation of the Phase I/II clinical trial with Spheramine in patients with Parkinson's disease. The Company now has six products in human clinical trials. >> First rule is do not harm. Second, if you can prove marginal efficiency, well someone will sell drug. Now in PIII (I guess registration one) trial means CeaVac is worming up. Who manufacture drug for them? They didn't mentioned Pivanex trial completion, so my guess is that ASCO should be right place for first news if there is something to report? Miljenko